194 related articles for article (PubMed ID: 12939188)
21. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
[TBL] [Abstract][Full Text] [Related]
22. [Association between IgG antibody against the C-terminal region of the preS1 protein of hepatitis B virus and the early response to interferon therapy in chronic hepatitis B].
Xia GM; Zhang ZH; Wei SF; Gao YF; Zhang TT; Zhang L; Li X
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):1-4. PubMed ID: 20128959
[TBL] [Abstract][Full Text] [Related]
23. High dose lamivudine and hepatitis B.
Musher DR; Wasser WG; Saggi SJ
Am J Gastroenterol; 1999 Nov; 94(11):3372. PubMed ID: 10566751
[No Abstract] [Full Text] [Related]
24. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.
Chang ML; Chien RN; Yeh CT; Liaw YF
J Hepatol; 2005 Jul; 43(1):72-7. PubMed ID: 15896869
[TBL] [Abstract][Full Text] [Related]
25. To stop or not to stop: the quest for long-term viral suppression.
Fung J; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2011 Mar; 26(3):420-2. PubMed ID: 21332537
[No Abstract] [Full Text] [Related]
26. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
27. [HBeAg-negative chronic hepatitis].
Ibragimova MM; Krel' PE; Abdurakhmanov DT
Ter Arkh; 2004; 76(2):87-91. PubMed ID: 15106425
[No Abstract] [Full Text] [Related]
28. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
[TBL] [Abstract][Full Text] [Related]
29. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
30. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
Hacker HJ; Zhang W; Tokus M; Bock T; Schröder CH
Ann N Y Acad Sci; 2004 Jun; 1022():271-81. PubMed ID: 15251972
[TBL] [Abstract][Full Text] [Related]
31. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
Jang JW; Choi JY; Bae SH; Yoon SK; Kim CW; Nam SW; Lee CD; Lee YS; Cha SB; Chung KW
J Med Virol; 2005 Nov; 77(3):367-73. PubMed ID: 16173025
[TBL] [Abstract][Full Text] [Related]
32. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
33. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.
Nikolaidis NL; Giouleme OI; Tziomalos KA; Saveriadis AS; Grammatikos N; Doukelis P; Voutsas AD; Vassiliadis T; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis NP
J Gastroenterol Hepatol; 2005 Nov; 20(11):1721-5. PubMed ID: 16246192
[TBL] [Abstract][Full Text] [Related]
34. Sustained response after lamivudine treatment in HBe minus chronic hepatitis B.
Madonia S; Tinè F; Malizia G; Giannuoli G; Concetta Cascioni M; Di Stefano R
J Hepatol; 2004 May; 40(5):870-1. PubMed ID: 15094240
[No Abstract] [Full Text] [Related]
35. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
[TBL] [Abstract][Full Text] [Related]
36. Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression.
Price N; Boxall EH
J Antimicrob Chemother; 2007 Dec; 60(6):1189-92. PubMed ID: 17913721
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
[TBL] [Abstract][Full Text] [Related]
38. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between hepatitis B virus markers and quantitative HBV DNA in serum].
Huang ZX; Chen DY; Zhang QB
Zhonghua Gan Zang Bing Za Zhi; 2004 Jan; 12(1):43. PubMed ID: 14761284
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
